Pethema Foundation
Clinical trials sponsored by Pethema Foundation, explained in plain language.
-
New pill combo offers hope for older leukemia patients who Can't handle chemo
Disease control Not yet recruitingThis study tests whether taking two oral medications (decitabine and ivosidenib) together can control acute myeloid leukemia (AML) in patients aged 60+ or those too frail for standard chemo. About 50 participants will take the pills in 28-day cycles until the disease worsens or s…
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New triple therapy aims to boost survival in frail AML patients
Disease control Not yet recruitingThis phase 3 trial will test whether adding the drug quizartinib to the standard two-drug combination (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 376 people aged 18 and older who cannot receive intens…
Phase: PHASE3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for leukemia patients: immunotherapy added to standard care
Disease control Not yet recruitingThis study tests a new treatment plan for adults up to 65 years old with a type of leukemia called Ph-negative ALL. The goal is to see if adding an immunotherapy drug called blinatumomab improves survival compared to the previous treatment plan. About 330 participants will receiv…
Phase: NA • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New study examines belantamab combos for myeloma relapse
Knowledge-focused Not yet recruitingThis observational study will review medical records of about 100 adults with multiple myeloma that has returned after initial treatment. Researchers want to see how well belantamab mafodotin given with other drugs (bortezomib and dexamethasone, or pomalidomide and dexamethasone)…
Sponsor: PETHEMA Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC